PubMed Health⌕ Search

Biomedical subjects

V Llaca Rodríguez

Publications and source records attributed to V Llaca Rodríguez.

7 recordsLinked to original sources
PubMed2000

[Comparative evaluation of bone mineral density in Mexican women using x-ray bone densitometry and ultrasound].

With lifestyle changes in women, smoking and use of beverages with caffeine, and sedentarism increasing, so the risk factors for decalcification, increase; which is a public health problem by the higher incidence of osteoporotic fractures, as the age advances, specially in the postmenopause woman, which means a greater secondary morbidity-mortality; an important cause of physical disability, which directly affects psychoemotional wellbeing in women. In this study two methods of bone densitometry, were used; one of x ray, and other with ultrasound in 138 women during postmenopause with an average index of corporal mass of 29. Both results were compared of bone density, T measurement with osteopenia and osteoporosis. Double densitometry, was done in the 138 patients of lumbar spine with DEXA equipment, and of calcaneum with DTU-one equipment, by the same technician, finding the difference of T punctuation in this double study.

Absorptiometry, Photon↗
PubMed1990

[Terconazol in vaginal candidiasis. Comparative study].

The antimycotic action and tolerance to terconazole in patients with vaginal candidiasis, were evaluated in a blind study. The medication was given in vaginal ovules (VO) 240 mg, one dose per day, and 80 mg one daily dose for three days; as compared to chlotrimazole, VO 200 mg, daily dose for three days. The patients presented with vaginal candidiasis demonstrated by Nickerson culture medium. Sixty patients were studied in three equivalent groups. The mates of patients treated with terconazole had no treatment; and the mates of patients treated with chlotrimazole received urinary acidifying medication. Symptomatology and mycologic findings were evaluated at 10 and 28 days post treatment. Mycological cure rates at 10 days were: 90 per cent for the terconazole group, 240 mg, one dose; and 95 per cent for patients with terconazole, 80 mg, daily dose for three days; or chlotrimazole, 200 mg, daily dose for three days. Twenty eight days post-treatment, laboratory tests were positive again: 50%, 40% and 15%, respectively. Recidive in patients treated with terconazole, is explained by lack of treatment in mates. In conclusion, terconazole offers a high percentage of clinical and mycological cure in vaginal candidiasis, and it is indispensable treatment for the mate, in order to avoid recidives.

Adult↗
PubMed1990

[Terconazole in vaginal candidiasis. A comparative study].

The antimycotic action and tolerance to terconazole in patients with vaginal candidiasis, were evaluated in a blind study. The medication was given in vaginal ovules (VO)240 mg, one dose per day, and 80 mg one daily dose for three days; as compared to chlotrimazole, VO 200 mg, daily dose for three days. The patients presented with vaginal candidiasis demonstrated by Nickerson culture medium. Sixty patients were studied in three equivalent groups. The mates of patients treated with terconazole had no treatment; and the mates of patients treated with chlotrimazole received urinary acidifying medication. Symptomatology and mycologic findings were evaluated at 10 and 28 days post treatment. Mycological cure rates at 10 days were: 90 per cent for the terconazole group, 240 mg, one dose; and 95 per cent for patients with terconazole, 80 mg, daily dose for three days; or chlotrimazole, 200 mg, daily dose for three days. Twenty eight days post-treatment, laboratory tests were positive again: 50%, 40% and 15%, respectively. Recidive in patients treated with terconazole, is explained by lack of treatment in mates. In conclusion, terconazole offers a high percentage of clinical and mycological cure in vaginal candidiasis, and it is indispensable treatment for the mate, in order to avoid recidives.

Adult↗